Treatment
Standard systemic therapy clinical trials
We’re tracking 317 recruiting studies that include Standard systemic therapy, each written for real people, not researchers, below.
Recruiting studies
- NCT06769113RecruitingPhase 2
Study of HLX43 for advanced esophageal cancer
This trial tests a new drug, HLX43, for people with advanced esophageal squamous cell carcinoma that has stopped responding to or cannot tolerate standard treatments. It aims to see if HLX43 can help shrink or control the cancer.
Jinan, ShandongAges 18–75 - NCT06719362RecruitingPhase 1
Testing a new cancer drug alone and with other therapies
This trial tests an experimental drug called M3T01, either alone or combined with pembrolizumab and other standard treatments, for people with advanced solid tumors or glioblastoma. The goal is to see if it is safe and effective.
Portland, OregonAges 18 years+ - NCT06726421RecruitingPhase 3
Systemic therapy with or without radiation for kidney cancer that has spread to a few spots
This trial compares standard systemic therapy (medication) alone versus systemic therapy plus targeted radiation to the cancer spots for people with kidney cancer that has spread to a limited number of places (up to 5 spots). It aims to see if adding radiation helps control the cancer better.
Fuzhou, FujianAges 18 years+ - NCT06588634Recruiting
A study of a catheter device for high-risk pulmonary embolism
This trial tests a new treatment for people with a severe, high-risk pulmonary embolism (blood clot in the lung). It uses a catheter device to remove the clot and help the heart work better.
New Haven, ConnecticutAges 18 years+ - NCT06564324RecruitingPhase 3
Comparing taletrectinib to standard therapy for ROS1-positive lung cancer
This study compares a new targeted therapy pill (taletrectinib) to standard treatments for people with advanced ROS1-positive lung cancer. The goal is to see if taletrectinib works better at shrinking tumors and delaying cancer growth.
Hefei, AnhuiAges 18 years+ - NCT04385290RecruitingPhase 1/Phase 2
Testing midostaurin plus gemtuzumab for newly diagnosed AML
This trial studies whether combining two medicines—midostaurin and gemtuzumab (with standard chemotherapy)—can improve outcomes for newly diagnosed acute myeloid leukemia (AML). It is testing a first-line treatment plan tailored to specific genetic changes in the leukemia.
München, BavariaAges 18–75 - NCT06338995RecruitingPhase 3
Lebrikizumab for nasal polyps and sinusitis
This trial tests a new injectable medicine (lebrikizumab) for people with chronic sinusitis and nasal polyps that steroid treatments haven't controlled. It aims to reduce polyp size and improve breathing, smell, and congestion.
Birmingham, AlabamaAges 12 years+ - NCT04428554RecruitingPhase 2
Radiation to control bladder cancer spread after no growth
This trial tests whether giving focused radiation (SBRT) to a few remaining metastatic spots can stop bladder cancer from progressing after initial chemotherapy or immunotherapy has worked. It may help patients who still have up to three remaining distant lesions but are not getting worse.
AlbiAges 18 years+ - NCT05675410RecruitingPhase 3
Testing two-drug treatment versus standard for Hodgkin lymphoma
This Phase 3 study compares today’s standard treatment for classic Hodgkin lymphoma with a new combination using brentuximab vedotin and nivolumab. The goal is to see which approach works better and is safe for newly diagnosed patients with early-stage disease.
Birmingham, AlabamaAges 5–60 - NCT05286814RecruitingPhase 2
Pump-delivered therapy plus chemo for liver-metastatic cancers
This phase 2 study tests a liver-targeted medicine delivered through a special implanted pump, combined with standard chemo, for cancers that spread mainly to the liver. It may help control tumor growth in the liver and improve outcomes compared with standard treatment alone.
Bethesda, MarylandAges 18–120 - NCT05276310RecruitingPhase 1
Study of IMC-002 in advanced cancer
This study tests a new drug called IMC-002 in people with advanced cancer that has not responded to standard treatment. It aims to see if the drug is safe and effective, and may be given alone or with other treatments depending on the cancer type.
Goyang-siAges 19 years+ - NCT02945579Recruiting
Testing skipping breast surgery or radiation for top responders
This trial studies whether some people with early-stage breast cancer who respond extremely well to hormone/chemo/targeted treatment can safely skip breast surgery and/or radiation. It aims to reduce side effects without increasing cancer risk in carefully selected patients.
Gilbert, ArizonaAges 30 years+ - NCT07438496RecruitingPhase 3
Study of nipocalimab for moderate to severe lupus
This trial tests a new medicine, nipocalimab, for adults with moderate to severe lupus. It aims to see if the drug can help control lupus symptoms and reduce disease activity.
Beverly Hills, CaliforniaAges 18–75 - NCT06513429Recruiting
IM19 CAR-T cell therapy for tough lupus cases
This trial tests whether a new type of immune cell therapy, called IM19 CAR-T, can help people with lupus that hasn't gotten better with standard treatments. It is designed for people ages 18 to 65 with moderate to severe disease activity.
Beijing, Beijing MunicipalityAges 18–65 - NCT07604805Recruiting
Chinese herbal medicine for severe lung blood pressure
This trial tests whether Qishen Yiqi Dropping Pills, a traditional Chinese herbal medicine, can safely improve symptoms and heart function in people with severe pulmonary hypertension (abnormally high blood pressure in the lungs). You would take this medicine alongside or instead of other treatments to see if it helps you walk farther and feel better.
Guangzhou, GuagdongAges 18–75 - NCT06637150RecruitingPhase 3
Dalpiciclib with hormone therapy for early breast cancer
This trial tests whether adding the drug dalpiciclib to standard hormone therapy improves outcomes for people with a certain type of early breast cancer (hormone receptor-positive, HER2-negative). It may help lower the risk of the cancer coming back.
ShanghaiAges 18–70 - NCT06643962Recruiting
Venetoclax plus strong chemo for AML with slow blast clearance
This trial tests adding venetoclax (a targeted pill) to strong chemotherapy for people with newly diagnosed AML. It is for those whose leukemia cells do not clear quickly enough after standard induction therapy, to see if the combination helps them achieve remission.
Nantong, JiangsuAges 18–70 - NCT05556460Recruiting
Device trial for fixing severe tricuspid valve leakage without surgery
This trial tests the DragonFly-T system to improve symptoms and heart function in people with severe tricuspid regurgitation (a leaky heart valve) using a catheter-based repair. It may help reduce valve leak–related symptoms when standard medication isn’t enough and surgery risk is higher.
Chengdu, SichuanAges 18 years+ - NCT07736651Recruiting
Anti-inflammatory diet and physical therapy for children with psoriasis
This trial tests if adding a gluten-free, low-histamine anti-inflammatory diet, and in some cases physical therapy, helps children with mild-to-moderate plaque psoriasis. It aims to see if these lifestyle changes can improve skin symptoms when combined with usual treatment.
Giza, Ad DokiAges 6–17 - NCT06919029Recruiting
New insulin pump study for children with new type 1 diabetes
This study tests a new insulin pump system (MiniMed 780G) in children aged 7-17 who were recently diagnosed with type 1 diabetes. It aims to see if this pump helps control blood sugar better and improves quality of life compared to standard insulin shots or older pumps.
AthensAges 7–17 - NCT06327477RecruitingPhase 1/Phase 2
A new type of radiation for newly diagnosed retroperitoneal sarcoma
This trial tests a new way of giving radiation called proton spatially fractionated radiotherapy (P-SFRT) combined with standard radiation for people with a type of sarcoma in the back of the belly. The goal is to see if this combination can treat the tumor more effectively.
Chicago, IllinoisAges 18 years+ - NCT06753812Enrolling by invitation
Lower limb therapy for children with unilateral cerebral palsy
This trial tests a therapy called constraint-induced movement therapy (CIMT) for the legs in children with unilateral cerebral palsy. It aims to improve leg function by encouraging use of the affected leg through structured exercises and activities.
BoluAges 5–15 - NCT04992780RecruitingPhase 2
Hypo-fractionated radiation versus standard radiation for lung cancer
This study compares two different radiation schedules for stage III non-small cell lung cancer, both combined with chemotherapy and immunotherapy. It aims to see whether giving radiation in a different way can work as well (or better) and be safe while treating the cancer.
Kansas City, KansasAges 18 years+ - NCT07856394Recruiting
Adding a special type of radiation to standard palliative radiation
This study tests whether adding a special type of radiation to standard palliative radiation helps reduce symptoms like pain, shortness of breath, or bleeding. It's for people with tumors that can't be removed and are large.
Scottsdale, ArizonaAges 15 years+
Common questions
- Are there clinical trials studying Standard systemic therapy?
- Yes. Clin2 currently lists 317 recruiting studies that include Standard systemic therapy, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Standard systemic therapy trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Standard systemic therapy an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Standard systemic therapy or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.